title: Scalp psoriasis: a promising natural treatment.
abstract: Psoriasis is a lifelong chronic inflammatory disease affecting 2-3% of the worldwide population. Scalp psoriasis is a particular form of psoriasis characterized by lesions on the scalp, which may occur isolated or in association with other skin lesions. The aim of this study was to investigate the efficacy and safeness of an innovative treatment of scalp psoriasis, which is based on the topical application of natural products. Fifty adult subjects with scalp psoriasis (23 females, 27 males) from different European dermatological centres were included in the study. Forty-six patients with severely infiltrated psoriatic lesions were invited to use the products of Dr Michaels® (Soratinex®), according to a three-phase application, twice a day (morning and evening). The other 4 patients followed a different regimen: after a shampoo in the evening, they applied the conditioner in the night and washed it in the morning with the cleansing gel. The application time of Dr Michaels® (Soratinex®) products was 8 weeks. The treatment was evaluated at 0, 1, 2, 3, 4, 5, 6, 7, and 8 weeks. The evaluation was based on the Psoriasis Scalp Severity Index (PSSI) and on a photographic analysis at each of the medical evaluation points. At the end of the study, all patients showed an outstanding improvement. Five patients referred a transient pruritus, which regressed spontaneously without discontinuing the application. No other side effects have been described. We observe that Dr Michaels® (Soratinex®) natural product family can be considered as a valid therapeutic tool for scalp psoriasis when considering the exclusion criteria. The tested products provided an outstanding improvement of lesions in all the patients, without side effects.
authors: Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany.
authors: U
authors: U
authors: Wollina
authors: 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
authors: J
authors: J
authors: Hercogovấ
authors: Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy.
authors: M
authors: M
authors: Fioranelli
authors: Dermatological Department University of Pisa, Pisa, Italy.
authors: S
authors: S
authors: Gianfaldoni
authors: Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria.
authors: A A
authors: AA
authors: Chokoeva
authors: Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria.
authors: G
authors: G
authors: Tchernev
authors: Psoriasis and Skin Clinic, Melbourne, Australia.
authors: M
authors: M
authors: Tirant
authors: PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic.
authors: F
authors: F
authors: Novotny
authors: University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India.
authors: M G
authors: MG
authors: Roccia
authors: Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria.
authors: G K
authors: GK
authors: Maximov
authors: Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy.
authors: K
authors: K
authors: França
authors: Chair of Dermatology, University of Rome G. Marconi Rome, Italy.
authors: T
authors: T
authors: Lotti
mesh_terms: D000287:Administration, Topical; D000328:Adult; D001688:Biological Products / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005060:Europe; D005260:Female; D006203:Hair Preparations / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011565:Psoriasis / Q000188:drug therapy / Q000473:pathology* / Q000628:therapy*; D012535:Scalp / Q000187:drug effects* / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D001688:Biological Products; D006203:Hair Preparations